Telomir Pharmaceuticals, Inc | WebDisclosure

Basculer en Français

11083	Companies
243214	Keywords
171376	Articles
130949	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 06/05/2025 at 14:30, 1 year 3 months ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival

Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF

published on 06/02/2025 at 14:35, 1 year 3 months ago

Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025

Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF

published on 06/02/2025 at 14:35, 1 year 3 months ago

Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025

Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE

published on 06/02/2025 at 14:30, 1 year 3 months ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026

BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF

published on 05/29/2025 at 14:35, 1 year 3 months ago

Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF

published on 05/29/2025 at 14:35, 1 year 3 months ago

Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA

Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE

published on 05/29/2025 at 14:30, 1 year 3 months ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress

Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF

published on 05/15/2025 at 14:05, 1 year 4 months ago

Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections

Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF

published on 05/15/2025 at 14:05, 1 year 4 months ago

Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments

Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE

published on 05/15/2025 at 14:00, 1 year 4 months ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens

Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex

Accesswire

Published on 09/25/2026 at 15:00, 2 minutes ago

HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/25/2026 at 14:00, 1 hour 2 minutes ago

Karbon-X (OTCQB:KARX) to Present Global Growth Strategy and Showcase SkyXero at 26th MK-Equity Investment Conference in Munich
Published on 09/25/2026 at 13:00, 2 hours 2 minutes ago

Core Silver Announces Grant of Stock Options
Published on 09/25/2026 at 13:00, 2 hours 2 minutes ago

American Hotel Income Properties REIT LP Announces Corporate Update
Published on 09/25/2026 at 13:00, 2 hours 2 minutes ago

UraniumX Plans Winter Gravity Program at Murphy Lake as Q4 Assays Approach

View all ACCESSWIRE

EQS Group

Published on 09/25/2026 at 14:58, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/25/2026 at 14:57, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/25/2026 at 14:56, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/25/2026 at 14:56, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/25/2026 at 14:55, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc

Les Echos

Published on 09/25/2026 at 07:00, 8 hours 1 minute ago

ENGIE mobilise une aide exceptionnelle de 54 millions d'euros pour soutenir les ménages les plus fragiles face à la hausse des prix de l'énergie
Published on 09/24/2026 at 18:31, 20 hours 30 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 20 hours 52 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 21 hours 2 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 21 hours 2 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026

View all LES ECHOS COMFI WIRE